Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery

Autor:	Robert D. Rosenberg, Elena Santagostino, Pier Mannuccio Mannucci, Kenneth A. Bauer, G Tagariello, F Baudo, A Gringeri
Rok vydání:	1994
Předmět:	medicine.medical_specialty business.industry Factor X Hematology Surgical procedures medicine.disease Thrombosis Surgery chemistry.chemical_compound Coagulation chemistry medicine In patient business Prospective cohort study Ex vivo Factor IX medicine.drug
Zdroj:	Thrombosis and Haemostasis. 71:737-740
ISSN:	2567-689X 0340-6245
DOI:	10.1055/s-0038-1642515
Popis:	SummaryPurer factor IX (FIX) concentrates have been produced for the treatment of hemophilia B in the attempt to reduce the risk of thrombotic complications associated with the use of prothrombin complex concentrates. To evaluate ex vivo whether or not FIX concentrates activate the coagulation system in conditions associated with a high risk for thrombosis, we measured markers of hypercoagulability in 10 patients with hemophilia B who underwent surgery, mainly orthopedic procedures, covered by multiple concentrate infusions (40-80 U/kg/day). Postinfusion plasma levels of prothrombin fragment 1+2 and factor X activation peptide did not differ significantly from the presurgical levels, neither before nor after each concentrate dose. Therefore, it appears that prolonged treatment of patients with hemophilia B undergoing high risk surgical procedures with high doses of FIX concentrate does not cause systemic activation of coagulation. This suggests that purified FIX concentrates are preferable to prothrombin complex concentrates for conditions associated with an increased risk of thrombosis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f1213f75d626716dac4f8cff26cb419b https://doi.org/10.1055/s-0038-1642515 Zobrazit plný text záznamu